----item----
version: 1
id: {E96DF559-DC5C-479B-8E80-2361D038BC4D}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/09/06/Correction Gender biases at Actelion Bayer and BI not significant
parent: {199B8802-DA9B-45D7-BE07-8E7DA944A744}
name: Correction Gender biases at Actelion Bayer and BI not significant
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 96c413cc-e5a8-41de-9812-7c1f343a5838

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 116

{38CC267C-7BFB-437D-BEA0-27DBA7B77873}|{B2967A9C-ABDA-4628-A672-9EDDCD142AEA}|{728904A1-7259-48E8-8256-60D002A0BFEA}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 68

Correction: Gender biases at Actelion, Bayer, and BI not significant
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 65

Correction Gender biases at Actelion Bayer and BI not significant
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 9137

<p>Despite having no female members on their senior executive boards, Actelion, Bayer and Boehringer Ingelheim were wrongly accused by <i>Scrip</i> of demonstrating statistically significant gender bias.</p><p>In an <a href="http://www.scripintelligence.com/home/Congratulations-You-have-an-all-male-executive-team-358682" target="_new">earlier article</a>, <i>Scrip</i> said that 16 of the 39 largest drug companies in Europe and North America had a level of gender bias in their upper management echelons that would meet a test of statistical significance at the 5% significance level. However, Actelion, Bayer and BI &ndash; each of which has five people, all men, in its top stratum &ndash; do not reach that level of significance (p=0.0503284).</p><p>Apologies, gentlemen, apologies!</p><p>The error was caused by an inappropriate use of probability methods. Scrip's mis-step was to use a Chi-squared test in the calculation of probabilities, a method familiar to those looking at the significance of data from clinical trials. However, <i>Scrip</i>'s findings and analysis attracted the attention of a prominent Harvard professor who pointed out that the Chi-squared approach provides only approximation of probabilities: it is appropriate in analyzing large numbers but not the small numbers <i>Scrip</i> was dealing with.</p><p><i>Scrip</i>'s revised statistical analysis calculates exact binomial probabilities that a management board of a given size (Column 2, Table 1) would contain the observed number of women (Column 3, Table 1), or fewer, simply by chance, given a base population of pharma employees that is 45% female.*</p><p>The results are shown below in Table 1.</p><p>Indeed, in Bayer's case, with its overall employee base of just over 37% women, an all-male senior team could arise by chance nearly 10% of the time (p=0.099). That's no doubt reassuring to those who have watched Bayer's 2013 <a href="http://#https://www.youtube.com/all_comments?v=pJuD-GoQEfk" target="_new">Youtube</a> tutorial on culture and gender balance in management.</p><p>None of the numbers <i>Scrip</i> presented on the gender balance within the upper echelons of pharmaceutical companies was incorrect, apart from the probabilities. So it remains the case that nine of the 39 companies we looked at have no women at all in their senior executive tiers. No company team has more than 30% women, and most have under 20%. </p><p>The nine companies with no female members in their senior executive teams are, in descending order of pharmaceutical sales, Novartis, Bayer, Novo Nordisk, Boehringer Ingelheim, Servier, Regeneron, STADA, Lundbeck, and Actelion. </p><table><h2>Table 1. Statistically significant gender bias at 13 out of 39 pharma companies</h2><tbody><tr><td><p><uri ref="">Company<p>&nbsp;</uri></td><td><p>Senior exec members</p>&nbsp;</td><td><p>Women senior executives</p>&nbsp;</td><td><p>New outcome</p>&nbsp;</td><td><p>New p value</p>&nbsp;</td></tr><tr><td><p>AbbVie</p>&nbsp;</td><td><p>8</p>&nbsp;</td><td><p>2</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.22</p>&nbsp;</td></tr><tr><td><p>Actavis</p>&nbsp;</td><td><p>10</p>&nbsp;</td><td><p>2</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.0996</p>&nbsp;</td></tr><tr><td><p>Actelion</p>&nbsp;</td><td><p>5</p>&nbsp;</td><td><p>0</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.05</p>&nbsp;</td></tr><tr><td><p>Alexion Pharmaceuticals</p>&nbsp;</td><td><p>10</p>&nbsp;</td><td><p>2</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.0996</p>&nbsp;</td></tr><tr><td><p>Amgen</p>&nbsp;</td><td><p>26</p>&nbsp;</td><td><p>6</p>&nbsp;</td><td><p>Gender bias</p>&nbsp;</td><td><p>0.018</p>&nbsp;</td></tr><tr><td><p>AstraZeneca</p>&nbsp;</td><td><p>13</p>&nbsp;</td><td><p>3</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.093</p>&nbsp;</td></tr><tr><td><p>Baxter International</p>&nbsp;</td><td><p>5</p>&nbsp;</td><td><p>1</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.256</p>&nbsp;</td></tr><tr><td><p>Bayer</p>&nbsp;</td><td><p>5</p>&nbsp;</td><td><p>0</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.05</p>&nbsp;</td></tr><tr><td><p>Biogen</p>&nbsp;</td><td><p>12</p>&nbsp;</td><td><p>2</p>&nbsp;</td><td><p>Gender bias</p>&nbsp;</td><td><p>0.042</p>&nbsp;</td></tr><tr><td><p>Boehringer Ingelheim</p>&nbsp;</td><td><p>5</p>&nbsp;</td><td><p>0</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.05</p>&nbsp;</td></tr><tr><td><p>Bristol-Myers Squibb</p>&nbsp;</td><td><p>10</p>&nbsp;</td><td><p>3</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.26</p>&nbsp;</td></tr><tr><td><p>Celgene</p>&nbsp;</td><td><p>8</p>&nbsp;</td><td><p>1</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.063</p>&nbsp;</td></tr><tr><td><p>Eli Lilly</p>&nbsp;</td><td><p>13</p>&nbsp;</td><td><p>3</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.093</p>&nbsp;</td></tr><tr><td><p>Endo International</p>&nbsp;</td><td><p>7</p>&nbsp;</td><td><p>1</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.102</p>&nbsp;</td></tr><tr><td><p>Ferring</p>&nbsp;</td><td><p>5</p>&nbsp;</td><td><p>1</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.256</p>&nbsp;</td></tr><tr><td><p>Galderma</p>&nbsp;</td><td><p>9</p>&nbsp;</td><td><p>2</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.15</p>&nbsp;</td></tr><tr><td><p>Gilead Sciences</p>&nbsp;</td><td><p>10</p>&nbsp;</td><td><p>2</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.0996</p>&nbsp;</td></tr><tr><td><p>GlaxoSmithKline</p>&nbsp;</td><td><p>13</p>&nbsp;</td><td><p>2</p>&nbsp;</td><td><p>Gender bias</p>&nbsp;</td><td><p>0.027</p>&nbsp;</td></tr><tr><td><p>Hospira</p>&nbsp;</td><td><p>13</p>&nbsp;</td><td><p>2</p>&nbsp;</td><td><p>Gender bias</p>&nbsp;</td><td><p>0.027</p>&nbsp;</td></tr><tr><td><p>Ipsen</p>&nbsp;</td><td><p>7</p>&nbsp;</td><td><p>1</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.102</p>&nbsp;</td></tr><tr><td><p>Johnson & Johnson</p>&nbsp;</td><td><p>16</p>&nbsp;</td><td><p>2</p>&nbsp;</td><td><p>Gender bias</p>&nbsp;</td><td><p>0.0066</p>&nbsp;</td></tr><tr><td><p>Lundbeck</p>&nbsp;</td><td><p>3</p>&nbsp;</td><td><p>0</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.166</p>&nbsp;</td></tr><tr><td><p>Mallinckrodt</p>&nbsp;</td><td><p>11</p>&nbsp;</td><td><p>2</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.065</p>&nbsp;</td></tr><tr><td><p>Menarini</p>&nbsp;</td><td><p>15</p>&nbsp;</td><td><p>2</p>&nbsp;</td><td><p>Gender bias</p>&nbsp;</td><td><p>0.0107</p>&nbsp;</td></tr><tr><td><p>Merck & Co</p>&nbsp;</td><td><p>12</p>&nbsp;</td><td><p>2</p>&nbsp;</td><td><p>Gender bias</p>&nbsp;</td><td><p>0.042</p>&nbsp;</td></tr><tr><td><p>Merck KGaA</p>&nbsp;</td><td><p>6</p>&nbsp;</td><td><p>1</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.163</p>&nbsp;</td></tr><tr><td><p>Mylan</p>&nbsp;</td><td><p>5</p>&nbsp;</td><td><p>1</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.256</p>&nbsp;</td></tr><tr><td><p>Novartis</p>&nbsp;</td><td><p>12</p>&nbsp;</td><td><p>0</p>&nbsp;</td><td><p>Gender bias</p>&nbsp;</td><td><p>0.00077</p>&nbsp;</td></tr><tr><td><p>Novo Nordisk</p>&nbsp;</td><td><p>9</p>&nbsp;</td><td><p>0</p>&nbsp;</td><td><p>Gender bias</p>&nbsp;</td><td><p>0.0046</p>&nbsp;</td></tr><tr><td><p>Pfizer</p>&nbsp;</td><td><p>13</p>&nbsp;</td><td><p>3</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.093</p>&nbsp;</td></tr><tr><td><p>Regeneron</p>&nbsp;</td><td><p>7</p>&nbsp;</td><td><p>0</p>&nbsp;</td><td><p>Gender bias</p>&nbsp;</td><td><p>0.015</p>&nbsp;</td></tr><tr><td><p>Roche</p>&nbsp;</td><td><p>11</p>&nbsp;</td><td><p>2</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.065</p>&nbsp;</td></tr><tr><td><p>Sanofi</p>&nbsp;</td><td><p>12</p>&nbsp;</td><td><p>2</p>&nbsp;</td><td><p>Gender bias</p>&nbsp;</td><td><p>0.042</p>&nbsp;</td></tr><tr><td><p>Servier</p>&nbsp;</td><td><p>9</p>&nbsp;</td><td><p>0</p>&nbsp;</td><td><p>Gender bias</p>&nbsp;</td><td><p>0.0046</p>&nbsp;</td></tr><tr><td><p>Shire</p>&nbsp;</td><td><p>5</p>&nbsp;</td><td><p>1</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.256</p>&nbsp;</td></tr><tr><td><p>STADA</p>&nbsp;</td><td><p>3</p>&nbsp;</td><td><p>0</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.166</p>&nbsp;</td></tr><tr><td><p>Teva</p>&nbsp;</td><td><p>9</p>&nbsp;</td><td><p>1</p>&nbsp;</td><td><p>Gender bias</p>&nbsp;</td><td><p>0.0385</p>&nbsp;</td></tr><tr><td><p>UCB</p>&nbsp;</td><td><p>10</p>&nbsp;</td><td><p>2</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.0996</p>&nbsp;</td></tr><tr><td><p>Valeant Pharmaceuticals</p>&nbsp;</td><td><p>8</p>&nbsp;</td><td><p>1</p>&nbsp;</td><td><p>NS</p>&nbsp;</td><td><p>0.063</p>&nbsp;</td></tr><tr><td><p><b>All companies</b></p>&nbsp;</td><td><p><b>370</b></p>&nbsp;</td><td><p><b>58</b></p>&nbsp;</td><td><p><b>Gender bias</b></p>&nbsp;</td><td><p><b>3.3x10<sup>-33</sup></b></p>&nbsp;</td></tr></tbody><tr><td colspan="5"><p>NS &ndash; Not significant at the 0.05 level of significance</p></td></tr></table><p><h3>*Pharma's base population</h3><p>Scrip has assumed a ratio of 45% women within the base population of each company surveyed. Although data on gender balance within pharma is patchy, this assumption is consistent with the data published by some companies: Novartis (46% women), Sanofi (45%), AbbVie (50%), and Bayer (37%).</p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 207

<p>Despite having no female members on their senior executive boards, Actelion, Bayer and Boehringer Ingelheim were wrongly accused by <i>Scrip</i> of demonstrating statistically significant gender bias.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 65

Correction Gender biases at Actelion Bayer and BI not significant
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150906T180003
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150906T180003
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150906T180003
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028991
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 68

Correction: Gender biases at Actelion, Bayer, and BI not significant
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

200100955
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{092B08D7-150F-4630-9C64-5389604B69D9}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358867
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042404Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

96c413cc-e5a8-41de-9812-7c1f343a5838
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042404Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
